In the global epidemic situation, most countries adopted the strategy of closing cities to delay the epidemic, which resulted in economic shutdown; the related economic losses were greater than the financial turmoil in 2008, and this wave of economic recession may last until 2021 or even longer. Therefore, in addition to the public health level of epidemic control this time, how to reopen the society and revive the economy is more important to all countries. According to the current list of global vaccine candidates listed by WHO, the countries/ pharmaceutical manufacturers most likely to launch vaccines are as follows: ChAdOx1-S: co-developed with
AstraZeneca by whatsapp database the University of Oxford, UK AD5-nCoV (recombinant new coronavirus adenovirus vector vaccine): jointly developed by China's CanSino Biologics Inc. and Beijing Institute of Biotechnology LNP-encapsulated mRNA: A collaboration between Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) Under the "showing muscles" of these three countries, it is not difficult to see the economics of vaccines. In addition to the competitive relationship between the United States and China as the world's economic leaders, there is also the economic gap of the United Kingdom after Brexit. It is hoped that this vaccine can improve the economy. a handful. From vaccine research and development to international rescue, there is "
Vaccine politics" behind it In the face of the market demand of the public health crisis of the global pandemic, vaccine research and development has not only invested in the R&D resources of pharmaceutical companies, the government, and the public, but also invested in the hope of restoring the economy to the right track. Therefore, vaccine development not only solves the public interests of the immediate public health crisis and economic recession, but also includes the conflicting issues of private interests under pressure from the pharmaceutical and biotechnology industry.